Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von HC Wainwright 

Regulus Therapeutics Inc. diskutieren

Regulus Therapeutics Inc.

WKN: A3DNZ4 / Symbol: RGLS / Name: Regulus Therapeutics / Aktie / Micro Cap /

7,05 €
-0,70 %

Einschätzung Buy
Rendite (%) 0,00 %
Kursziel 8,41
Veränderung
Endet am 19.09.24

Regulus Therapeutics Inc. (NASDAQ: RGLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Ratings data for RGLS provided by MarketBeat

Einschätzung Buy
Rendite (%) -40,48 %
Kursziel 5,51
Veränderung
Endet am 18.03.25

Regulus Therapeutics Inc. (NASDAQ: RGLS) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $6.00 price target on the stock.
Ratings data for RGLS provided by MarketBeat

Einschätzung Buy
Rendite (%) -54,92 %
Kursziel 8,30
Veränderung
Endet am 25.03.25

Regulus Therapeutics Inc. (NASDAQ: RGLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Ratings data for RGLS provided by MarketBeat

Einschätzung Buy
Rendite (%) 211,95 %
Kursziel 8,35
Veränderung
Endet am 06.05.25

Regulus Therapeutics Inc. (NASDAQ: RGLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Ratings data for RGLS provided by MarketBeat

Einschätzung Buy
Rendite (%) 279,03 %
Kursziel 9,34
Veränderung
Endet am 25.06.25

Regulus Therapeutics Inc. (NASDAQ: RGLS) had its price target raised by analysts at HC Wainwright from $9.00 to $10.00. They now have a "buy" rating on the stock.
Ratings data for RGLS provided by MarketBeat

Einschätzung Buy
Rendite (%) 400,00 %
Kursziel 6,36
Veränderung
Endet am 14.08.25

Regulus Therapeutics Inc. (NASDAQ: RGLS) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $7.00 price target on the stock.
Ratings data for RGLS provided by MarketBeat

Einschätzung Buy
Rendite (%) 407,25 %
Kursziel 9,11
Veränderung
Endet am 08.10.25

Regulus Therapeutics Inc. (NASDAQ: RGLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Ratings data for RGLS provided by MarketBeat

Einschätzung Buy
Rendite (%) 373,15 %
Kursziel 9,22
Veränderung
Endet am 30.10.25

Regulus Therapeutics Inc. (NASDAQ: RGLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Ratings data for RGLS provided by MarketBeat

Einschätzung Buy
Rendite (%) 434,09 %
Kursziel 9,39
Veränderung
Endet am 11.11.25

Regulus Therapeutics Inc. (NASDAQ: RGLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Ratings data for RGLS provided by MarketBeat

Einschätzung Buy
Rendite (%) 414,60 %
Kursziel 9,22
Veränderung
Endet am 14.03.26

Regulus Therapeutics Inc. (NASDAQ: RGLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Ratings data for RGLS provided by MarketBeat

Einschätzung Buy
Rendite (%) 373,15 %
Kursziel 5,57
Veränderung
Endet am 27.03.26

Regulus Therapeutics Inc. (NASDAQ: RGLS) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $6.00 price target on the stock, up previously from $3.00.
Ratings data for RGLS provided by MarketBeat

Regulus Therapeutics Inc. (NASDAQ: RGLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for RGLS provided by MarketBeat

Regulus Therapeutics Inc. (NASDAQ: RGLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for RGLS provided by MarketBeat